Cargando…

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients

OBJECTIVE: The use of once-daily dual-release HC (DR-HC) in primary adrenal insufficiency (PAI) is often associated with benefits in metabolic parameters when compared to immediate-release HC (IR-HC). In this study, we evaluated the effects on clinical, biochemical and metabolic parameters of switch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delle Cese, Francesca, Corsello, Andrea, Cintoni, Marco, Locantore, Pietro, Pontecorvi, Alfredo, Corsello, Salvatore Maria, Paragliola, Rosa Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883639/ https://www.ncbi.nlm.nih.gov/pubmed/33597926 http://dx.doi.org/10.3389/fendo.2020.610904

Ejemplares similares

Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency
por: Bannon, Christopher A. M., et al.
Publicado: (2021)

Pediatric Cushing's Disease and Pituitary Incidentaloma: Is This a Real Challenge?
por: Paragliola, Rosa Maria, et al.
Publicado: (2014)

Medical Approaches in Adrenocortical Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2020)

Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis
por: Paragliola, Rosa Maria, et al.
Publicado: (2017)

Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia
por: Cera, Gianluca, et al.
Publicado: (2022)

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
por: Guarnotta, V, et al.
Publicado: (2019)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Factors Predicting Time to TSH Normalization and Persistence of TSH Suppression After Total Thyroidectomy for Graves' Disease
por: Paragliola, Rosa Maria, et al.
Publicado: (2019)

Cortisol circadian rhythm and jet-lag syndrome: evaluation of salivary cortisol rhythm in a group of eastward travelers
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023)

Cushing’s Syndrome Effects on the Thyroid
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2021)

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy
por: Dineen, Rosemary A, et al.
Publicado: (2023)

Treating Hypopituitarism in the Over 65s: Review of Clinical Studies
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection
por: Locantore, Pietro, et al.
Publicado: (2021)

Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study
por: Guarnotta, Valentina, et al.
Publicado: (2019)

Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency
por: Frigerio, Sofia, et al.
Publicado: (2023)

Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency
por: Gasco, V., et al.
Publicado: (2022)

Genetic Basis of ACTH-Secreting Adenomas
por: Locantore, Pietro, et al.
Publicado: (2022)

Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
por: Nilsson, A G, et al.
Publicado: (2014)

SAT-381 Cognitive Function and Quality of Sleep in Patients with Adrenal Insufficiency May Benefit by Therapy with Dual-Release Hydrocortisone
por: Krekeler, Clarissa, et al.
Publicado: (2019)

46,XY Disorder of Sex Development Caused by 17α-Hydroxylase/17,20-Lyase Deficiency due to Homozygous Mutation of CYP17A1 Gene: Consequences of Late Diagnosis
por: Papi, Giampaolo, et al.
Publicado: (2018)

A Prospective Cross-Over Study of Tissue Glucocorticoid Metabolism in Patients With Adrenal Insufficiency: The Effects of Dual-Release Hydrocortisone Therapy
por: Dineen, Rosemary Anne, et al.
Publicado: (2021)

The Interplay between Immune System and Microbiota in Osteoporosis
por: Locantore, Pietro, et al.
Publicado: (2020)

A novel MEN1 pathogenic variant in an Italian patient with multiple endocrine neoplasia type 1
por: Corsello, Andrea, et al.
Publicado: (2020)

Obesity Is a Marker of Reduction in QoL and Disability
por: Sirtori, Anna, et al.
Publicado: (2012)

A rare case of juvenile hypertension: coexistence of type 2 multiple endocrine neoplasia -related bilateral pheochromocytoma and reninoma in a young patient with ACE gene polymorphism
por: Paragliola, Rosa Maria, et al.
Publicado: (2015)

Validation of the Dutch version of the Swallowing Quality-of-Life Questionnaire (DSWAL-QoL) and the adjusted DSWAL-QoL (aDSWAL-QoL) using item analysis with the Rasch model: a pilot study
por: Simpelaere, Ingeborg S., et al.
Publicado: (2017)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017)

Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020)

Clinical Concepts on Thyroid Emergencies
por: Papi, Giampaolo, et al.
Publicado: (2014)

The Importance of Connection to Others in QoL in MSA and PSP
por: Wiblin, Louise, et al.
Publicado: (2017)

Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia
por: Karunasena, Nayananjani, et al.
Publicado: (2017)

Exenatide Alters Absorption of Hydrocortisone in a Diabetic Patient With Panhypopituitarism: Iatrogenic Adrenal Insufficiency
por: Fujita, Yukari, et al.
Publicado: (2013)

Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
por: Quinkler, Marcus, et al.
Publicado: (2016)

Quality of life (QoL) for people with primary sclerosing cholangitis (PSC): a pragmatic strategy for identifying relevant QoL issues for rare disease
por: Marcus, Elena, et al.
Publicado: (2022)

Iodine Supplementation: Usage “with a Grain of Salt”
por: Prete, Alessandro, et al.
Publicado: (2015)

SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
por: Simeoli, Chiara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7a4hca582preb45ef86mldlkrc